Riskpilot← Back to searchSign inGet full accessNORDIC BIOTECH HOLDING ApS
APSActiveCVR 26409683Slotsmarken 12, 1. thResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20011 employees
Revenue 2024
DKK -41K
-94% vs 2023
EBITDA margin
104.1%
+93% vs 2023
Equity ratio
29.0%
Financial strength
Net profit 2024
DKK -39K
+92% vs 2023
| Revenue | DKK -41K | -94% |
| EBITDA | DKK -42K | +93% |
| Net profit | DKK -39K | +92% |
| Total assets | DKK 507K | -51% |
| Equity | DKK 147K | -75% |
| Employees | 1 | — |
Legal name
NORDIC BIOTECH HOLDING ApS
CVR number
26409683
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. december 2001
Share capital
DKK 125.200
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en direktør
Company purpose
Selskabets formål er besiddelse af aktier og anparter i helt eller delvist ejede datterselskaber samt enhver aktivitet, der efter direktionens skøn står i forbindelse hermed.
Address
Slotsmarken 12, 1. th
Phone
+4530595030
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 477 | 0 | -392 | -88 | -36 | 130 | -169 | -697 | 442 | 325 | 114 | -627 | -41 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -3 | -6 | -10 | -21 | -2 |
| EBITDA | -287 | -148 | -446 | -88 | -36 | 130 | -169 | -697 | 438 | 319 | 103 | -647 | -42 |
| Depreciation & amort. | -0 | -0 | -0 | -76 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -287 | -148 | -446 | -165 | -36 | 130 | -169 | -697 | 438 | 319 | 103 | -647 | -42 |
| Net financials | 169 | -29 | -42 | -1 | -46 | 900 | -89 | 10 | -113 | -9 | -8 | -0 | -7 |
| Profit before tax | -118 | -177 | -489 | -165 | -82 | 1.030 | -259 | -688 | 325 | 310 | 96 | -648 | -49 |
| Tax | 9 | -0 | -0 | -0 | -0 | -33 | 33 | -0 | -0 | 5 | -0 | -133 | -10 |
| Net profit | -127 | -177 | -489 | -165 | -82 | 1.063 | -292 | -688 | 325 | 305 | 96 | -515 | -39 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.435 | 1.257 | 816 | 608 | 404 | 1.285 | 1.013 | 125 | 549 | 1.045 | 1.107 | 1.025 | 507 |
| Equity | — | -57 | -547 | -790 | -872 | 191 | -100 | -788 | -462 | 758 | 854 | 578 | 147 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.316 | 1.315 | 1.362 | 1.399 | 1.276 | 1.094 | 1.113 | 913 | 1.012 | 287 | 253 | 447 | 360 |
| Total debt | 1.316 | 1.315 | 1.362 | 1.399 | 1.276 | 1.094 | 1.113 | 913 | 1.012 | 287 | 253 | 447 | 360 |
EBITDA margin
-4234000.0%
This company
15.8%
Market median
-26797568% vs market
20122024
Equity ratio
29.0%
This company
38.2%
Market median
-24% vs market
20122024
Return on equity
-26.7%
This company
18.4%
Market median
-245% vs market
20122024
Net profit margin
-3927800.0%
This company
8.1%
Market median
-48491458% vs market
20122024
Asset turnover
-0.08×
This company
1.12×
Market median
-107% vs market
20122024
Debt / equity
2.45×
This company
0.62×
Market median
-295% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TB Management | Management | 2025 | — | — |
SG | Founder | 2001 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
FINANSMANAGEMENT ApS | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
FINANSMANAGEMENT ApS
NORDIC BIOTECH HOLDING ApS Board members of NORDIC BIOTECH HOLDING ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Torsten Bjørn | Management | 0 companies |
| Sigbjørn Georg Nielsen Kjærgård | Founder | 0 companies |